Virus-directed enzyme prodrug therapy utilizing the bacterial enzyme nitroreductase delivered by a replication-defective adenovirus vector to activate the prodrug CB1954 is a promising strategy currently undergoing clinical trials in patients with a range of cancers. Similarly, selectively replicating oncolytic adenoviruses are entering clinical trials. An understanding of interactions between vector and target cell are critical to the development of these strategies. We demonstrate that adenovirus vectors activate cellular pathways that promote cell survival in an NF-kB-dependent manner, and consequently have a negative effect on the efficacy of cell killing induced by cancer gene therapy strategies. This provides a potential therapeutic target to enhance the cytotoxicity of these approaches.
Introduction
Gene therapy is emerging as a novel treatment modality for cancer, offering the theoretical advantage of specific targeting of the tumour site to reduce unwanted systemic toxicity that is often a dose-limiting component of conventional cytotoxic therapy, while maximizing antitumour effects. Several strategies have been developed, including immunogene therapy (eg cytokine gene insertion); mutant gene correction (eg p53); oncolytic virus therapy; and enzyme-prodrug activation (virus-directed enzyme prodrug therapy (VDEPT)). All these approaches are reliant upon an efficient vector system to deliver the therapeutic effect specifically to the tumour. E1-deleted replication-defective adenovirus (RAd) vectors have been frequently used in cancer gene therapy clinical trials because of their wide tissue tropism, ability to infect dividing and nondividing cells, and relative ease of manipulation in tissue culture to carry a variety of therapeutic transgenes. 1 Recently, adenovirus has been engineered to lack E1B 55 kDa virus protein, which normally inactivates p53, to facilitate lytic infection of wild-type virus. This deletion allows selective replication in cells with a defective p53 response resulting in specific tumour cell lysis. Such conditionally replicating adenoviruses are showing promise in early-phase clinical trials. 2 We have undertaken phase I clinical trials utilizing a novel enzyme-prodrug combination in which an E1-, E3-deleted RAd (CTL102) is used to deliver the bacterial enzyme, nitroreductase (NR), to tumours in order to activate the systemically administered prodrug CB1954 to a potent alkylating agent locally at the tumour site. 3, 4 Furthermore, in an effort to increase transgene delivery we have constructed a conditionally replicating oncolytic E1B-attenuated adenovirus to deliver NR with promising preclinical results. 5 It is known that wild type and attenuated adenovirus can interact with cellular signalling pathways in a range of human cell types as part of the infective life cycle. For example, both the NF-kB and MAP kinase pathways are reported to be activated by adenovirus infection of respiratory epithelium, endothelial cells, hepatocytes and antigen-presenting cells. [6] [7] [8] [9] [10] To date, there are no reports regarding these effects in human cancer cells. Since such pathways play a central role in the regulation of apoptosis and in inflammatory and immune responses, these events may have a significant influence upon the efficacy and toxicity of adenovirus cancer gene therapy.
This study addresses the effect of replication-defective and conditionally replicating adenovirus gene therapy vectors on cellular signalling pathways in a number of human cancer cell lines.
Results

RAd vectors attenuate the sensitivity of human carcinoma cell lines to a range of chemotherapeutic agents
In a previous study, we investigated the interaction of the novel VDEPT gene therapy system, combining NR with the prodrug CB1954, and conventional cytotoxic chemotherapy. 11 We observed a synergistic interaction between NR/CB1954 and 5-fluorouracil (5-FU) when NR was delivered via an E1-, E3-deleted adenovirus vector (RAd-NR) at multiplicities of infection (moi), 1-10. However, synergy was lost when RAd-NR was administered at higher moi. . (e) SKOV3 cells were infected as above and 24 h later cells were exposed to topotecan (0.05 mg/ml); doxorubicin (0.5 mM); paclitaxel (0.01 mM); 5-FU (10 mM). After 48 h, the proportion of apoptosis to necrosis was determined by Syto 16 assay. Results are the mean of three separate experiments 7s.e. Figure 1 ). Infection by RAd-NR resulted in reduced chemosensitivity to all drugs tested. This effect was dose dependent, being most marked at moi 100, where IC 50 's were up to 20-fold higher than in mock-infected cells (Table 1) . These results were corroborated using the Syto 16 assay, which can distinguish apoptotic from necrotic cell death in a quantitative manner. 12 This confirmed that drug-induced cell death was predominantly apoptotic and that RAd infection significantly reduced the level of apoptosis induced by all drugs used (Figure 1d) . Similar results were observed in an early passage ovarian cancer cell line (MG79), primary cancer cells derived directly from ascites of a patient with ovarian cancer (OVKM), and two human colon cancer cell lines (SW480, WiDr) (data not shown). Similar results were also seen when these cell lines were infected with other E1-, E3-deleted adenovirus vectors (RAd-35, RAd-GFP), confirming that this effect is independent of the transgene being carried (Table 1 and data not shown).
RAds are reported to induce G2/M cell cycle arrest in infected cells in a dose-dependent manner. [13] [14] [15] Indeed, we have demonstrated that the viruses used in this study also induce G2/M arrest (data not shown). Since many chemotherapeutic agents are cell cycle specific, the contribution of RAd-induced G2/M arrest to drug sensitivity was assessed. Cell cycle arrest was induced in SKOV3 cells by serum starvation and cells were then infected by RAd (-NR, -35, -GFP) and exposed to chemotherapeutic agents as before. Although serum starvation alone did reduce chemosensitivity, this was further significantly reduced following RAd infection (data not shown).
Taken together, these data indicate that infection of human carcinoma cells by RAd can induce resistance to a range of chemotherapeutic agents by a mechanism that is independent of effects on cell cycle progression. Since these drugs induce cell death predominantly by caspasedependent apoptosis, we postulated that RAd infection could stimulate antiapoptotic cellular pathways rendering cells less sensitive to chemotherapy. 16 RAd activates NF-kB in human carcinoma cell lines Since wild-type adenovirus and RAd are known to induce NF-kB activation in a range of other cell types and since activation of this pathway plays a pivotal role in the regulation of apoptosis, we examined whether RAd infection induced NF-kB in human cancer cells.
NF-kB is sequestered in the cytoplasm by the regulatory protein IkBa. A critical component of NF-kB activation is its dissociation from IkBa to allow relocalization to the nucleus where it acts as a transcriptional activator. This is mediated by serine-32 phosphorylation of IkBa, which then undergoes proteosomal degradation.
To assess the effect of RAd infection on phosphorylation of IkBa in human cancer cells, SKOV3 cells were infected with RAd-NR and samples were harvested at serial time points. Cell lysates were analysed by Western blotting using an antibody specific for the serine-32 phosphorylated form of IkBa. RAd-NR rapidly induced IkBa phosphorylation, within 5 min of infection ( Figure  2a ). Concurrently, a decrease in total IkBa was observed (Figure 2a) . A similar effect was seen following infection with RAd-35 but not following mock infection (data not shown).
To confirm NF-kB nuclear activity in human cancer cells in response to RAd infection, SKOV3 cells were infected by RAd-NR or were mock infected. After 2 h, samples were harvested and nuclear extracts were analysed by electrophoretic mobility shift assay (EMSA) for NF-kB binding activity. TNFa, a potent activator of NF-kB, was used as a positive control. Robust activation of NF-kB DNA binding activity was observed following RAd infection (Figure 2b ). Active NF-kB complexes comprised dimers of p50 and p65 but not c-Rel as indicated by supershift analysis (Figure 2c ).
To further quantify these effects, and to assess the effect of various chemical inhibitors, Hela cells expressing a stable NF-kB luciferase reporter were employed. Cells were infected with RAd-NR or RAd-35 at 1, 10, or 100 moi, or were mock infected, and luciferase activity was assessed 8 h postinfection. This demonstrated a clear dose-dependent increase in luciferase activity induced by RAd infection (Figure 2d ).
NF-kB activity can be inhibited by: (i) interfering with proteosomal degradation of its inhibitor, IkBa, using the proteosome inhibitor TLCK; (ii) inhibiting the dissociation of NF-kB from IkB using BAY11-7082; (iii) expression of an excess of IkBa via a RAd, RAd-IkB. The effect of these inhibitors on RAd-induced NF-kB activation was examined. Hela NF-kB reporter cells were infected with RAd-NR (moi 100). Again, at 8 h a clear increase in luciferase activity was observed. Infection with RAd-IkB (moi 10) 24 h prior to RAd-NR infection reduced luciferase activity to approximately the level induced by RAd-NR moi 10 ( Figure 2b and e). Similarly, preincubation with either TLCK or BAY11-7082 significantly inhibited NF-kB activation ( Figure 2e ).
Inhibition of NF-kB restores chemosensitivity to RAd-infected human carcinoma cell lines
In order to investigate whether the reduced chemosensitivity induced by infection with RAd was mediated by NF-kB activation, the effect of NF-kB inhibitors was assessed.
SKOV3 cells were infected by RAd-NR (moi 100) and 24 h later exposed to topotecan. Assessment of cytotoxicity by MTT a further 48 h later confirmed a reduction in chemosensitivity in virus-infected cells (Figure 3a) . However, pretreatment with NF-kB inhibitors partially restored chemosensitivity (Figure 3b-d) . Syto 16 analysis Adenovirus vectors and inhibition of apoptosis DH Palmer et al indicated that this effect was mediated predominantly via an increase in apoptosis with NF-kB inhibition ( Figure 3e ). Similar results were observed with other drugs (doxorubicin, paclitaxel, 5-FU) and in other cell lines (MG79, OVKM, SW480, WiDr; data not shown). This effect was not mediated by an effect of the inhibitors on RAd-induced changes in cell cycle progression (data not shown). Importantly, the chemotherapeutic agents used in this study did not themselves induce NF-kB activation. Furthermore, NF-kB inhibitors did not enhance the cytotoxic effects of these drugs in the absence of RAd 
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infection and nor were the inhibitors themselves inherently cytotoxic at the concentrations used (data not shown).
The effects of NF-kB inhibitors are not mediated by inhibition of adenovirus infection of cancer cells since no reduction in NR expression measured by Western blotting (RAd-NR); b-galactosidase activity measured by colorimetric assay (RAd-35); or GFP expression measured by flow cytometry (RAd-GFP), is seen following preincubation with inhibitors prior to infection with the relevant adenovirus (data not shown).
Inhibition of NF-kB enhances cytotoxicity induced by RAd-NR/CB1954 VDEPT gene therapy
The use of RAd-NR delivered by direct intratumoural injection followed by systemic administration of the prodrug CB1954 as the basis of a novel VDEPT combination is currently in early-phase clinical trials. 3, 4 We have previously demonstrated that activated CB1954, in common with other cytotoxic agents, kills cells predominantly by apoptosis. 11 We therefore postulated that NF-kB activation by the adenovirus vector may actually attenuate the cytotoxicity of CB1954 and, further, that inhibition of NF-kB may enhance cytotoxicity. In order to test this, SKOV3 cells were infected by RAd-NR with or without preincubation with the NF-kB inhibitors RAdIkB, TLCK, or BAY11-7082. After 48 h, cells were exposed to CB1954 over a range of concentrations and a further 48 h later cell viability was assessed by MTT. As previously reported, infection with RAd-NR resulted in a several hundred-fold sensitization of SKOV3 cells to CB1954 compared to uninfected cells. Pretreatment with NF-kB inhibitors further sensitized RAd-NR-infected cells to CB1954 by up to an additional 10-fold (Figure  4a-c) . This increased cytotoxicity was predominantly (e) SKOV3 cells were infected as above and 24 h later were exposed to topotecan (0.05 mg/ml). After 48 h, the proportion of apoptosis to necrosis was determined by Syto 16 assay. Results are the mean of three separate experiments 7s.e.
Adenovirus vectors and inhibition of apoptosis DH Palmer et al due to an increase in apoptotic cell death. Following infection with RAd-NR (moi 100) and exposure to CB1954 (10 mM), NF-kB inhibition enhanced apoptosis by greater than 50% (Figure 4d ). NF-kB inhibitors did not affect the sensitivity of SKOV3 cells to CB1954 in the absence of RAd-NR. Furthermore, sensitivity to CB1954 of SKOV3 cells stably expressing NR was not affected by NF-kB inhibition, confirming the effects reported in this study to be adenovirus related (data not shown).
RAd induces cellular inhibitors of apoptosis, c-IAP 1 and c-IAP 2, in an NF-kB-dependent manner NF-kB is reported to transactivate the expression of a range of genes involved in the regulation of apoptosis. [17] [18] [19] [20] In order to investigate whether these may mediate 
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RAd-induced effects on chemosensitivity, the effect of RAd on a number of key apoptosis regulatory genes was assessed using RNAse protection assay (RPA). This allowed simultaneous analysis of changes in the expression of a number of genes following RAd infection. The RPA template used comprised a number of apoptosis regulatory genes with known or putative NF-kB binding sites in their promoter sequence (XIAP, bcl-xl, bcl-xs, bfl 1, c-IAP1, c-IAP2). SKOV3 cells were mock infected or infected with RAd-NR (moi 100) and mRNA was extracted at several time points. A clear increase in c-IAP 1 and c-IAP 2 mRNA was observed as early as 4 h following infection (Figure 5a ). This effect was partially inhibited by preincubation with NF-kB inhibitors (RAd-IkB, TLCK, BAY11-7082), confirming this to be an NF-kB-dependent effect (Figure 5b ).
RAd induces the inflammatory cytokine interleukin-6 (IL-6) in an NF-kB-dependent manner
As well as playing a central role in the regulation of apoptosis, NF-kB is also a key mediator of inflammatory responses to a range of external stimuli.
Infection of SKOV3 cells by RAd-NR or RAd-35 causes a rapid, dose-dependent increase in secretion of the proinflammatory cytokine IL-6 ( Figure 6 ). IL-6 secretion is abrogated by incubation with NF-kB inhibitors prior to adenovirus infection, indicating its dependence upon NF-kB ( Figure 6 ).
Conditionally replicating oncolytic adenoviruses activate NF-kB, inhibition of which enhances cytotoxicity
Viruses engineered to replicate selectively in tumour cells have the potential to infect a greater proportion of cells and to directly induce tumour cell lysis. Further, combination of such vectors with prodrug-activating gene therapy strategies by insertion of the appropriate 
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cDNA may facilitate increased transgene expression and consequently enhanced prodrug activation compared to replication-defective vectors.
To investigate the effect of conditionally replicating adenovirus on NF-kB activation, Hela NF-kB reporter cells were infected with dl1520 or CR-NR, a conditionally replicating oncolytic E1B-attenuated adenovirus engineered to deliver NR. A robust, dose-dependent increase in luciferase activity was observed, even at very low multiplicities of infection (Figure 7a) . Incubation with NF-kB inhibitors prior to infection abrogated this effect (Figure 7a) .
The effect of NF-kB inhibition on oncolytic virus toxicity, with and without combination with enzymeprodrug therapy, was assessed. SKOV3 cells were infected with dl1520 (moi 1). After 72 h, cell viability, measured by MTT, was reduced in infected cells to approximately 50% of that in mock-infected cells. As anticipated, in the absence of NR, the addition of CB1954 (50 mM) did not further enhance cytotoxicity. However, preincubation with NF-kB inhibitors did significantly further reduce cell viability (Figure 7b ). Infection of SKOV3 cells with CR-NR (moi 1) for 72 h was similarly cytotoxic and, in this setting, addition of CB1954 (50 mM) did further enhance cytotoxicity. This is important since it is possible that prodrug activation could, in fact, reduce the oncolytic effect of replicating adenovirus vectors by limiting virus replication. Preincubation with NF-kB inhibitors also enhanced CR-NR toxicity to a similar extent to that seen with CB1954 (50 mM). Furthermore, NF-kB inhibition further potentiated the toxicity of CR-NR/CB1954 combination treatment (Figure 7b ). The additional cell death induced by NFkB inhibition was again predominantly apoptotic as assessed by Syto 16 assay. Inhibition of NF-kB increased apoptosis induced by oncolytic adenovirus by up to 100% (Figure 7c ).
Discussion
The increasing use of replication-defective and conditionally replicating adenoviruses as gene therapy vectors and as laboratory tools necessitates an understanding of the effects of such vectors on cellular biological pathways that may influence the desired therapeutic effect.
Here, we report that RAd vectors stimulate such pathways in a number of human carcinoma cell lines. RAd infection results in phosphorylation of IkBa and the consequent nuclear relocalization of the transcription factor NF-kB. These events result in a resetting of the 'apoptotic threshold' of the infected cell mediated, in part, by NF-kB-dependent upregulation of the apoptosis regulatory genes c-IAP1 and c-IAP2. This is summarized in Figure 8 . Other NF-kB-dependent genes not investigated here are also likely to be upregulated.
These effects are of particular relevance to cancer gene therapy where the aim is to induce death of the target cell, such that activation of cellular survival pathways may negatively influence this goal. This study demonstrates that these effects result in reduced sensitivity to chemotherapeutic drugs in infected cells and also to RAd-mediated enzyme-prodrug therapy.
We have also demonstrated that conditionally replicating adenoviruses induce a robust activation of NF-kB, which, again, raises the apoptotic threshold of infected cells.
This study also provides potential therapeutic targets that may enhance the efficacy of adenoviral cancer gene therapy. We have shown that specific inhibitors of NF-kB can, indeed, increase the cytotoxicity of enzyme-prodrug gene therapy; enhance the toxicity of oncolytic virus therapy; and restore chemosensitivity to RAd-infected cells. The potential clinical relevance of this latter effect is exemplified by our previously reported finding of a synergistic interaction between activated CB1954 and 5-FU when NR is delivered using RAd-NR at low moi but not when higher titres of RAd-NR are used.
11 However, synergy is seen following preincubation with NF-kB inhibitors prior to infection with RAd-NR at higher moi (data not shown).
This study has demonstrated that NF-kB activation also mediates adenovirus-induced inflammatory effects as exemplified by an increased secretion of the proinflammatory cytokine IL-6. This will have clinically relevant implications for the use of NF-kB inhibitors with adenovirus-based therapy since inflammatory responses to the vector may potentially have both beneficial and harmful consequences in the context of cancer gene therapy. On the one hand, an inflammatory response to the vector localized to the tumour may enhance the antitumour effect. Conversely, a systemic inflammatory response may result in unwanted toxicity and may therefore limit the systemic delivery of such vectors. Such responses may also limit the utility of repeated administration of adenovirus vectors. In another study we have investigated the effect of adenovirus vectors on a number of other signalling pathways (manuscript submitted). We have confirmed that RAd infection activates the PI3-kinase/AKT pathway. Thus, AKT-dependent effects such as inhibition of caspase-9 and phosphorylation and consequent inhibition of the proapoptotic BAD may also contribute to antiapoptotic adenovirus effects. 21, 22 This is likely to explain why NF-kB inhibition does not fully restore chemosensitivity following RAd infection in the studies reported here.
Further, we have confirmed that RAd can activate the ERK MAPK pathway in human carcinoma cells, resulting in induction of COX-2. However, we have demonstrated that this does not contribute to the antiapoptotic effects of the vector, although it is likely that these pathways contribute to inflammatory responses to adenovirus and may therefore represent a useful therapeutic target.
The findings of the current study will be of clinical relevance to the further development of enzyme-prodrug gene therapy and oncolytic virus therapy, particularly when used in combination with conventional chemotherapy. Further, there is increasing use of conditionally replicating adenoviruses for the delivery of therapeutic genes as well as for their intrinsic oncolytic effect, for example to combine with a prodrug-activating strategy. However, this leads to a complex balance between the additional antitumour effect of prodrug activation and a potentially detrimental effect on viral oncolysis due to the antiviral effect of activated drug. Such interactions are likely to be even more complex in vivo. In the present study we have shown that NF-kB inhibition can enhance oncolytic virus toxicity to a similar extent as that induced by activated prodrug. Indeed, this approach, perhaps by integration of the IkBa gene into a conditionally replicating vector, may provide enhanced toxicity without the complex interplay seen with the incorporation of prodrug-activating enzymes.
A major limitation to the success of conditionally replicating adenoviruses in clinical trials to date is the restricted capacity for virus replication and distribution throughout the tumour mass. This process is governed by a number of factors including the timing of lytic virus burst and host immune/inflammatory responses. Since NF-kB plays a central role both in cell survival and inflammation, its manipulation may contribute to enhanced virus spread such that further study is warranted.
Materials and methods
Cells and cell culture
Cell lines used were: the human ovarian carcinoma cell line SKOV3; MG79, a low passage ovarian carcinoma cell line; OVKM, ovarian carcinoma cells derived directly from ascites of a patient with ovarian cancer; and two colorectal carcinoma cell lines, SW480 and WiDr. HeLa cells with a stable-transfected NF-kB luciferase reporter were the kind gift of Professor R Hay (University of St Andrews, UK).
Cell lines were maintained in DME with HEPES, 10% FCS and supplemented with glutamine. An E1B-55 kDa-deleted conditionally replicating adenovirus (dl1520) and an E1B-55 kDa-deleted adenovirus encoding nitroreductase (CR-NR) were also used (the kind gift of Dr M-J Chen, University of Birmingham, UK).
Adenovirus infection of cells
E1-, E3-RAd vectors encoding the
Cells were plated out at a density of 2 Â 10 6 cells/ml in 75 cm 3 flasks and allowed to adhere overnight. Medium was removed and cells exposed to adenovirus in 1 ml medium, with rocking every 20 min. After 2 h infection medium was removed and replaced with 12 ml fresh medium.
Inhibitors
The cell permeable inhibitors Na-p-tosyl-L-lysine-chloromethyl ketone, TLCK (100 mM, Sigma) and BAY11-7082 (10 mM, Calbiochem) were added to cells for 1 h prior to adenovirus infection. Inhibitor concentrations used were determined by the ability to inhibit the downstream effector induced by a positive control stimulus (TNFa 10 ng/ml), without being directly cytotoxic.
MTT assay
Cells were plated out at a density of 5 Â 10 4 /ml in 96-well plates and allowed to attach overnight prior to treatment. Following treatment, 20 ml MTT 10mg/ml (Sigma) in PBS were added to each well and incubated for 4 h at 371C and the formazan crystals formed were dissolved in DMSO. The absorbance was recorded at 550 nm.
Flow cytometric analysis of cell viability
Cells were plated out at a density of 2 Â 10 5 /ml in 48-well plates and allowed to attach overnight. Following treatment, cells were trypsinized and resuspended in 0.5 ml saline (prewarmed to 371C). Syto 16 (Molecular Probes Europe, Leiden, Netherlands) was added at a concentration of 25 nM and incubated with the cells at room temperature for 1 h, at which time 5 mg/ml propidium iodide was added. Samples were analysed immediately on a Coulter EPICS XL flow cytometer. A two-dimensional dot plot was generated of Syto 16 fluorescence versus propidium iodide fluorescence. Syto 16 is only taken up by viable cells and propidium iodide only enters cells whose membranes have become permeablized, therefore this technique distinguishes between viable cells (syto 16 +ve, propidium iodide Àve), apoptotic cells (syto 16 Àve, propidium iodide Àve) and necrotic cells (syto 16 Àve, propidium iodide +ve). Data for 10 000 cells was collected for each sample and prior to data collection cell debris was excluded by setting a gate on a forward versus side scatter two-dimensional dot plot.
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Electrophoretic mobility shift assay
Cells were harvested and washed in 500 ml PBS at 41C. Cell pellets were lysed in 10 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT. 0.2% NP40, 1 mM phenylmethylsulfonylfluoride, 10 mM leupeptin (Sigma) and 5 ml bovine aprotinin (Sigma). Lysates were microfuged at 16 000 g for 10 s and the cytoplasmic fraction removed. The nuclear pellet was resuspended in 100 ml buffer containing 20 mM HEPES (pH 7.9), 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.5 mM DTT, 0.2 mM EDTA and protease inhibitors as above. Lysates were incubated on ice for 10 min before microfugation at 16 000 g for 30 s. Supernatant was removed and protein concentration estimated by Biorad (Hercules, CA, USA) protein assay. Double-stranded oligonucleotides were end labeled using g-32P ATP (Amersham) and T4 polynucleotide kinase (Boehringer, Mannheim, Germany). For the detection of NF-kB binding activity, an oligonucleotide containing human immunodeficiency long terminal repeat (HIV-LTR) NF-kB consensus binding sequence (5 0 -GAT-CAG-GGA-CTT-TCC-GCT-GGG-GAC-TTT-CC-3 0 ) was used. Binding reactions containing 10 mM of nuclear protein extract, 1 mg poly-dI-dC (Pharmacia, Uppsala, Sweden), 0.1 ng of probe labeled to a specific activity of 2 Â 10 8 counts per min/mg DNA, and binding buffer containing 4% glycerol, 1 mM EDTA, 5 mM DTT, 0.01 M Tris/HCl (pH 7.5) and 5 mM KCl in a total volume 20 ml were incubated on ice for 30 min. Samples were loaded on to a 5% polyacrylamide gel in 0.5 Â TBE buffer (5 mM Tris/HCl, 0.5 mM EDTA, pH 7.5) and resolved by electrophoresis. Gels were dried and analysed by autoradiography. Supershift analysis was performed by preincubation of samples with antibodies (p50, Upstate; p65, Santa Cruz; c-Rel, Santa Cruz) prior to addition of radiolabelled probe.
Luciferase assay
Cells were harvested and washed twice in PBS. Cell pellets were lysed in 300 ml of reporter lysis buffer (100 mM Hepes, pH 8, 5 mM DTT, 2 mM MgCl 2 , 2% v/v Triton X-100). Lysates were microfuged at 16 000 g. Supernatant was removed and protein concentration was estimated by Biorad protein assay. In all, 50 ml of lysate 1 mg/ml was aliquoted into luminometer tubes in duplicate. The luciferase value was read using a Berthold Lumat LB 9570 luminometer primed with 100 ml luciferase assay reagent (for 100 ml reagent, 2 ml 1 M glycylglycine, pH 8, 1 ml 100 mM MgCl 2 , 20 ml 500 mM EDTA, 50.8 mg DTT, 27.8 mg ATP, 21.3 mg co-enzyme A and 93 ml GDW) immediately prior to use 250 ml 10 mM luciferin was added to 100 ml reagent, luciferin stock is made up in glycylglycine by adding 50 mg beetle luciferin (Promega) to 0.47 ml 1 M glycylglycine pH 8 and diluting in 15.3 ml GDW.
Western blotting
Cells were harvested, washed once in ice-cold PBS, pelleted by centrifugation and pellets lysed for 20 min on ice. Samples were pelleted at 13 000 r.p.m. at 41C and lysates decanted and stored at À701C. Protein concentrations of total cell lysates were determined using a Biorad (Hercules, CA, USA) assay. Total cell lysate protein (100 mg) was separated by SDS-PAGE and electroblotted onto nitrocellulose. Membranes were blocked with 5% milk in PBS-Tween or for detection of phosphorylated proteins, in TBS-Tween. Membranes were probed with rabbit polyclonal serine-32 phosphorylated IkBa antibody, 1:1000 (Cell Signaling Technology). Parallel studies were performed using primary antibody specific for the total protein. Immune complexes were detected with horseradish peroxidase-conjugated secondary antibody (anti-rabbit diluted 1:2000) and then visualized with ECL reagent (Amersham, UK) and autoradiography.
RNAse protection assay
RNA was extracted with the TRIzol reagent (Gibco BRL) according to the manufacturer's protocol. RPA was carried out using the RiboQuantt Multi-Probe RNAse Protection Assay System (PharMingen) according to the manufacturers instructions. For each sample, 20 mg RNA was used. 2 mg yeast tRNA was used as a background control. Samples were separated on a precast 6% TBE urea gel (Novex) with 0.5 Â TBE running buffer. Gels were dried and analysed on phosphorimager.
Enzyme-linked immunosorbent assay for detection of IL-6
Cells were plated out at a density of 2 Â 10 5 cells/well on a 24-well plate and allowed to adhere overnight. At 24 h after adenovirus infection, supernatant was collected and microfuged briefly to pellet cell debris. IL-6 ELISA was carried out using a Pellikinet kit according to the manufacturers instructions.
